At clinical stages, alongside with B7.1 and LFA-3, ICAM-1 is one of the TRI-COM costimulatory molecules which have been used as T cell response boosters in vaccines against different types of cancer in combination with other treatments or antigens [151,152,153]. Here, CD58 is linked to cancer.